What type of companies cannot be valued using the standard DCF model?

Just want to hearing other industry experts' opinions on what types of companies are not value-able using the standard DCF model (FCF-based). Currently I have the following:

  1. Banks (driven by loans/deposits)
  2. Insurance companies (driven by written premiums and claims)
  3. Private equities/other balance-sheet-based financial companies (driven by proprietary investments)
  4. REITs (driven by property assets)
  5. Business development companies (driven by value of portfolio companies)
  6. Biopharma (can't assign terminal value to patents, need multiple DCF to value different drugs)
  7. Mining (finite value dependent on individual mines)
  8. Oil & gas (finite value depended on oil/gas reserves)
  9. Utilities (regulated ROI)

Are these correct and are there any other type of companies that can't be valued using the standard DCF model?

4 Comments
 

Every industry is going to have some modified version of DCF that can value the business you're looking at.

I've valued REITs, O&G, pharma, banks using DCFs. It's just not the fastest way to do it. If your assumptions are consistent, you will end up with the same result.

 

Do a standard FCFE model. Normalize net income to be used as a proxy for FCFE and modify it based on regulatory capital constraints, same as any other company needing to retain a portion of their earnings/issue equity to grow revenues.

 

Est sit et sequi et sunt repudiandae laborum. Corrupti officia occaecati reiciendis sapiente quia repudiandae consequuntur. Modi autem enim voluptas magnam qui odit aut vel.

Quo commodi esse sit voluptates odio voluptatibus. Est asperiores ex est odit numquam. Voluptas eius quasi modi ad quo natus.

Saepe qui quis quo praesentium numquam. Temporibus exercitationem laborum fuga et. Quisquam exercitationem eum porro voluptatum.

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 08 98.4%
  • JPMorgan No 97.9%
  • Goldman Sachs 02 97.3%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.3%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (53) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (15) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”